Events

Virtual AI Summit w/ Kevin Garwood and Peju Oshisanya

Panel Discussion: AI x Policy: Driving Responsible and Scalable Data Governance Best Practice – Looking Ahead at How External Stakeholders and Governmental Regulations Will Influence Data Strategy

  • Multinational companies – transferring and accessing data across borders, given different jurisdictions/laws/regulations
  • Brexit and the future of GDPR
  • European Union/US/China – what’s next in tech policy? How will it change tech investment and innovation? What does it mean for private companies?
  • Data Diversity
Speakers
  • Richard Self - Senior Lecturer in Governance of Advanced and Emerging Technologies, University of Derby
  • Eline Chivot - Senior Policy Analyst, Center for Data Innovation
  • Edwina Dunn - Co-Founder & Board Member, dunnhumby & Centre for Data Ethics & Innovation
  • Peju Oshisanya - Director – Clinical Programme Leader, Benevolent AI
  • Mike Wiley - Application CTO and VP Engineering, F5

Healthcare Track: Data Diversity Effort at BenevolentAI

→ Register here


Peju Oshisanya
AI Ethics, Data Diversity Advocate, Clinical Drug Development Leader at BenevolentAI

Peju is an innovative operational strategy expert with over 15 years wide-ranging experience relating to strategic programme leadership, planning and management of clinical trials with responsibility for global clinical programmes. She has extensive experience in working in early drug discovery and exploratory phases focused on the transition of early stage assets to clinical development. She has held leadership positions in programme management responsible for key clinical programmes and assets within Eli Lilly, Sanofi Aventis, Pfizer and Takeda. In her current role at BenevolentAI, she is responsible for driving the asset strategy to maximise the value of both early and late phase drug development programmes.

Kevin Garwood
Patient Data Manager at BenevolentAI

Kevin is a patient data manager for precision medicine activities at BenevolentAI and is responsible for managing information governance concerns for patient-level data and in identifying and acquiring clinical and –omic data sources that would support our drug discovery programmes. Kevin’s interests include bioethics, intellectual property law and better understanding the value chain that shapes the worth and applicability of health data in the field of precision medicine. Most of his work involves coordinating with stakeholders from very different parts of the company.


More Posts

You Might Also Like

Blog
Tech Nation Visa: the gateway to world-leading UK tech jobs
Drawing attention to the Tech Nation Visa, a great initiative that enables the brightest international talent to live and work in the UK.
Feb 19, 2021
News
BenevolentAI announces first patient dosed in its Atopic Dermatitis clinical trial
A molecule designed and developed by BenevolentAI to treat mild to moderate Atopic Dermatitis has entered clinical trials.
Feb 11, 2021
News
BenevolentAI and AstraZeneca achieve collaboration milestone with novel AI-generated chronic kidney disease target
BenevolentAI and AstraZeneca hit collaboration milestone with an AI-generated CKD target from the partnership entering AstraZeneca’s portfolio.
Jan 27, 2021
News
ACTT-2 trial results published in the New England Journal of Medicine validate baricitinib’s efficacy in combination with remdesivir in hospitalised COVID-19 patients
Peer-reviewed data from the ACTT-2 further validate BenevolentAI’s hypothesis for baricitinib as a potential COVID-19 treatment.
Jan 15, 2021
Blog
Joanna Shields speaks at the Global Partnership on Artificial Intelligence
BenevolentAI CEO Joanna Shields opened the final plenary of the Global Partnership on Artificial Intelligence (GPAI) summit with a powerful message on the future of AI.
Dec 11, 2020
Blog
BenevolentAI wins Innovation Award at 2020 Scrip Awards
BenevolentAI wins the Innovation Award at the prestigious 2020 Scrip Awards for our work in artificial intelligence applied drug discovery.
Dec 11, 2020